Avx and the BOD are only offering you a share of the costly ph3 with big risk. Its the same situation as they had with ip-88. No partner, to validate the drug the only difference if the drug is spelt ACT not PI-88.
And don’t give me the spin, about “near term value inflection points” and “discussion with several parties” because we have heard it all before.
PGL Price at posting:
75.0¢ Sentiment: None Disclosure: Held
